Y Biologics Inc
Y Biologics Inc is a biotechnology company focused on the development and commercialization of monoclonal antibodies for oncology and autoimmune diseases.
Business. Y Biologics Inc is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the KOSDAQ under the ticker symbol 338840.KQ. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Y Biologics Inc is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the KOSDAQ under the ticker symbol 338840.KQ. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Y Biologics Inc maintains a strong liquidity position with cash and equivalents amounting to KRW 38,922,143,940, which significantly exceeds its total liabilities of KRW 29,200,450,880. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations. The current ratio of 36.16 further underscores the company's liquidity strength, as it holds a substantial amount of current assets relative to its current liabilities.
Despite its strong liquidity, Y Biologics Inc is currently unprofitable, with a net income of -KRW 42,024,660,500 and an operating income of -KRW 9,830,550,100. The company's return on equity (ROE) is -1.58, and its return on assets (ROA) is -0.7532, both of which are significantly below the industry median for biotechnology firms. These metrics indicate that the company is not generating returns for shareholders or effectively utilizing its assets.
Y Biologics Inc's revenue is concentrated in a single business segment, as disclosed in its latest financial filings. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in the United States. This concentration in a single segment and geographic region may expose the company to higher operational and market risks.
The company's growth trajectory is currently constrained by its negative operating and net income. Looking ahead, the company is expected to continue investing in research and development to bring new products to market. However, the path to profitability remains uncertain, and the company's free cash flow of -KRW 41,550,816,600 indicates ongoing cash burn.
Y Biologics Inc faces several risk factors, including the high costs associated with drug development and regulatory approval. The company's debt-to-equity ratio of 0.55 is relatively low, suggesting that it is not heavily leveraged. However, the risk assessment indicates a low probability of dilution in the near term, with no immediate filing-based liquidity or dilution flags detected.
Recent events, including filings and transcripts, have not indicated any significant changes in the company's strategic direction or financial health. The company continues to focus on its pipeline of monoclonal antibodies and is working to advance its clinical trials.
- Y Biologics Inc has a strong liquidity position with significant cash reserves.
- The company is currently unprofitable, with negative returns on equity and assets.
- Revenue and operations are concentrated in a single segment and geographic region.
- The company is expected to continue investing in R&D, but the path to profitability is uncertain.
- The risk of dilution is low, and there are no immediate liquidity concerns.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Y Biologics Inc Market data — financials · 2026-05-26